The methods currently used to diagnose and characterize NSCLC have limitations and may be inaccurate^1-3. Low concordance exists among laboratories and lack of concurrence is found among pathologists¹. In one study, up to 40% of squamous or adenocarcinomas of the lung were reclassified when evaluated by a second pathologist¹.

Unlike the methods currently used, miRview® squamous provides a differential diagnosis with:

• Fast, standardized, and objective classification
• The highest level of accuracy
• Simple interpretation
• Routine sample preparation

The miRview® squamous assay uses quantitative real-time PCR (qRT-PCR) to determine the expression of microRNAs in tumor tissue. The sensitivity and specificity of this assay have been shown to be 97% and 91%, respectively⁴.

miRview® squamous is based on formalin-fixed paraffin-embedded (FFPE) tumor samples, the current standard for preserving tumors in the post-op setting. FFPE samples require minimal preparation to be analyzed by our experts and can be easily shipped via any air courier.

1. Stang A, Pohlabeln H, Müller KM, Jahn I, Giersiepen K, Jöckel KH. Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study. Lung Cancer. 2006;52(1):29-36.
2. Field RW, Smith BJ, Platz CE, et al. Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review. J Natl Cancer Inst. 2004;96(14):1105-1107.
3. Perelman M, Rosenwald S, Spector Y, et al. MicroRNA biomarkers for differential diagnosis of lung tumors. Presented at: United States and Canadian Academy of Pathology Annual Meeting; March 7-13, 2009; Boston, MA. Abstract 1630.
4. Data on file, Rosetta Genomics.